Status: Not yet recruiting
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
Participants needed: 18
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: S&Ebio Co. Ltd.Updated: Aug 1, 2025Locations: 3
Eligibility criteria
Adults with 19 years or older [+8]
Pre-stroke disability (pre-stroke mRS ≥ 2) [+16]